These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 3727760)

  • 1. Cleaning up pertussis vaccine.
    Bannatyne RM; Jackowski J; Cheung R
    Vaccine; 1986 Jun; 4(2):91-2. PubMed ID: 3727760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effectiveness of an endotoxin-depleted pertussis vaccine.
    Bannatyne RM; Jackowski J
    Vaccine; 1987 Dec; 5(4):268-9. PubMed ID: 3433915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo effect of polymyxin B on pertussis vaccine.
    Larter WE; Corrigan JJ; Fulginiti VA
    Am J Dis Child; 1984 Mar; 138(3):281-3. PubMed ID: 6322572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evaluation of the pertussis component vaccine produced by apoceruloplasmin affinity chromatography.
    Ginnaga A; Morokuma K; Furukawa S; Shigaki T; Katsuki N; Aihara K; Oka T; Sakoh M; Tamura C; Imaizumi A
    Dev Biol Stand; 1991; 73():233-41. PubMed ID: 1778315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing the endotoxic activity of pertussis vaccine.
    Bannatyne RM; Cheung R
    J Hyg (Lond); 1981 Dec; 87(3):377-81. PubMed ID: 7310121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of endotoxin from antibody preparations for clinical use. Assessment of polymyxin-sepharose CNBr affinity chromatography.
    Lahiri VL; Srivastava RK; Hazra DK; Gupta AK; Painuly NK; Sharma SK; Khanna-Hazra P; Khanna P; Gupta RK; Pathak M
    Cell Biophys; 1994; 24-25():9-14. PubMed ID: 7736544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
    Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H
    Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.
    Sidey FM; Furman BL; Wardlaw AC
    Vaccine; 1989 Jun; 7(3):237-41. PubMed ID: 2781857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
    Vuolo AM; Lustigman B
    Biologicals; 1993 Mar; 21(1):45-52. PubMed ID: 8217117
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
    Gupta RK; Saxena SN; Sharma SB; Ahuja S
    Dev Biol Stand; 1991; 73():205-22. PubMed ID: 1778314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of gram-negative endotoxin from solutions by affinity chromatography.
    Issekutz AC
    J Immunol Methods; 1983 Jul; 61(3):275-81. PubMed ID: 6348159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
    Sato Y; Sato H
    Tokai J Exp Clin Med; 1988; 13 Suppl():79-88. PubMed ID: 2908530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Purification and analysis of the antigenicity of a 69,000 Da protein from Bordetella pertussis.
    Gould-Kostka JL; Burns DL; Brennan MJ; Manclark CR
    FEMS Microbiol Lett; 1990 Feb; 55(3):285-9. PubMed ID: 2323550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Removal of endotoxins by affinity sorbents.
    Anspach FB; Hilbeck O
    J Chromatogr A; 1995 Sep; 711(1):81-92. PubMed ID: 7496497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of macrophage response to brain injury. A new effect of pertussis vaccine possibly related to histamine-sensitizing factor.
    Levine S; Sowinski R
    Am J Pathol; 1972 May; 67(2):349-60. PubMed ID: 4553663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyxin and pertussis.
    Bannatyne RM
    Am J Dis Child; 1984 Dec; 138(12):1158. PubMed ID: 6095648
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of a pertussis component vaccine in Japan.
    Sato Y; Kimura M; Fukumi H
    Lancet; 1984 Jan; 1(8369):122-6. PubMed ID: 6140441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity and immunogenicity of a double-strength acellular pertussis vaccine.
    Blumberg DA; Chatfield PC; Cherry JD; Robinson RG; Smith K; Mabie L; Holroyd HJ; Baker LR; Dudenhoeffer FE; Apau N
    Vaccine; 1992; 10(9):614-6. PubMed ID: 1502839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the protective effects of the pertussis acellular vaccine with the component vaccine, which have different amounts of fimbriae, against the experimental aerosol infection of mice with Bordetella pertussis.
    Morokuma K; Ginnaga A; Nishihara T; Tsunoda S; Furukawa M; Aihara K; Sakoh M
    Dev Biol Stand; 1991; 73():223-32. PubMed ID: 1685713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of acellular pertussis vaccines.
    Sato Y; Sato H
    Biologicals; 1999 Jun; 27(2):61-9. PubMed ID: 10600185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.